Introduction
Valproic acid (2-propylpentanoic acid, VPA see Fig. 1 ) is generally regarded as the first choice agent for most idiopathic and symptomatic generalized epilepsies. 1 The therapeutic concentration of VPA ranges from 50 to 100 mg/ml. 2, 3 One of the most important clinical adverse effects ascribed to VPA therapy is liver failure. 4 Previous studies indicate that the incidence of hepatotoxicity caused by VPA is about 1 in 40,000 adults, 1 in 5000 children and 1 in 500 in the high-risk population in the late 1980s. 5 The multiple metabolic pathways involved in VPA biotransformation give rise to more than 50 known metabolites of the parent drug. 6 Several studies suggest that 2-propyl-4-pentenoic acid (4-ene VPA) is the most important teratogenic and hepatotoxic metabolite. [7] [8] [9] [10] [11] The structure of 4-ene VPA is closely related to the known hepatotoxicants, hypoglycin and 4-pentenoic acid (4-PA).
In a rat model, 4-ene VPA and its b-oxidation metabolite 2-propyl-2,4-pentadienoic acid (2,4-diene VPA see Fig. 2 ) can produce severe hepatic microvesicular steatosis. 12 Another study in rats showed that VPA hepatotoxicity is significantly correlated with liver concentrations of 4-ene VPA and that toxicity can be predicted by the urinary excretion of total 4-ene VPA. 11 All of these findings suggest that monitoring the concentration of VPA and 4-ene VPA in blood may help to reduce the risk of toxicity in humans and that a reliable quantitative method that allows simultaneous determination of VPA and 4-ene VPA in plasma is warranted. Although several methods have been established to detect the plasma concentrations of VPA and 4-ene VPA separately, [13] [14] [15] [16] [17] there are only two published reports describing simultaneous determination of VPA and 4-ene VPA using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) in human plasma collected from the United States 18 and China, 19 respectively. Although the method had good reproducibility and accuracy, it is commonly known that there are some limitations of HPLC-MS/MS in clinical pharmacokinetic monitoring. These are related to the ease of hardware and software use, the instrument performance, the practicability of HPLC-MS/MS assays in a routine laboratory setup, and last but not least to instrument costs, particularly for some developing countries like China. With the background mentioned above, the objectives of the present study were: (1) to develop a cost-effective, rapid and efficient method for the simultaneous separation and quantification of VPA and 4-ene VPA in human plasma by use of liquid-liquid extraction procedure and high performance liquid chromatography-ultraviolet (HPLC-UV) and (2) to evaluate the correlations of the plasma VPA and 4-ene VPA concentrations with clinical adverse effects such as hepatotoxicity in Chinese patients with epilepsy.
Subjects and methods

Patient enrollment and plasma sample collection
This study was carried out between November 2010 and May 2011 in 64 epileptic outpatients at the Department of Neurology at the First Affiliated Hospital of Sun Yat-sen University. All of the subjects (age 21.8 AE 16.1 years, body weight 51.9 AE 18.9 kg) were Southern Han Chinese in origin, and the demographic characteristics of the patients see Table 3 . All patients took divalproex sodium at 8-30 mg/kg/day twice daily as mono-therapy for at least 1 month. Samples were collected following patients' informed consent. Human plasma samples treated with anticoagulant sodium citrate from healthy plasma donors were obtained from the Central Laboratory of the Blood Transfusion Service of Guangzhou, Guangdong, China. Blood samples (2 ml) for drug assays were usually obtained about 12 h after the evening dose. The plasma was separated by centrifugation and kept at À80 8C until analysis. 
Preparation of standard solutions and quality control samples
The stock standard solutions were diluted with methanol to obtain working solutions at concentrations over 0.05-2.0 mg/ml for VPA and 5-200 mg/ml for 4-ene VPA. A standard stock solution of octanoic acid (IS) at 10 mg/ml in methanol was diluted to a working solution of 1 mg/ml. Stock solutions and working solutions were stored at À20 8C and 4 8C, respectively. The calibration standards and quality control (QC) samples were prepared by spiking blank human plasma with standard working solutions during validation and incorporated in each assay run. Calibration standards were made at concentrations of 5, 10, 20, 40, 80, 160 and 200 mg/ml for VPA and 0.5, 1, 2, 4, 8, 16 and 20 mg/ml for 4-ene VPA, respectively. Quality control samples were prepared at concentrations of 10, 40 and 160 mg/ml for VPA and 1, 4, and 16 mg/ml for 4-ene VPA, respectively (see Fig. 2 ).
Sample extraction and instrumental analyses
For blank samples, standard working solutions (20 ml of VPA, 4-ene VPA and IS, respectively) were added into 140 ml blank plasma sample in 10 ml centrifuge tube then vortex-mixed. The human plasma samples were acidified to pH 4 with hydrochloric acid (1 M, 200 ml) and extracted with ethyl acetate (1.5 ml, 5 min) by use of a vortex mixer for 1 min. After centrifugation at 4000 Â g for 10 min, the supernatant was transferred to a clean centrifuge tube and mixed with 10 ml triethylamine and 50 ml 2,4 0 -dibromoacetophenone solution (12 mg/ml in methanol). The mixture was held for 40 min in a water bath at 70 8C and then evaporated to dryness by general nitrogen gas. The residues were dissolved in 100 ml mobile phase. An aliquot (10 ml) of the reconstituent was injected into the HPLC for analysis. The chromatographic system (Waters, Avondale, CA) consisted of a pump (Waters 515), an automatic injector (Waters 717 plus), a UV detector (Waters 486), and a Workstation (Millennium32).
Waters XTerra MS C18 column (5 mm, 4.6 mm Â 150 mm, Waters, Milford, USA) was used for the separation. The mobile phase consisted of methanol/water (76:24, v/v). The analytes were separated by the analytical column at room temperature. Detection was performed at wavelength of 254 nm with a flow rate of 1 ml/min.
Method validation
The selectivity was investigated in six individual human plasma samples at the lower limit of quantification (LLOQ). The LLOQ was defined as the lowest concentration on the calibration curve of the analytes measured with acceptable precision and accuracy (i.e. relative standard deviation (RSD, refers to the absolute value of the coefficient of variation (CV)) and relative error < 20%) and with the response at least five times to the blank response (noise). Linearity was assessed by preparing and analyzing VPA and 4-ene VPA standard samples over 5-200 mg/ ml and 0.5-20 mg/ml, respectively, with seven concentration points in human plasma. For determining the intra-day accuracy and precision, five aliquots of QC samples of VPA and 4-ene VPA were analyzed on the same day. The inter-day accuracy and precision were assessed by analysis of five precision and accuracy batches on 5 different days. The stability of analytes was assessed by determining QC samples at three concentrations with five samples for each concentration, exposed to different storage conditions including room temperature for 4 h, three freeze-thaw cycles, and À20 8C for 1 month.
Biochemical analysis
Biochemical analysis was performed on serum samples using the Sysmex HST-330 system (Sysmex Corporation, Kobe, Japan). Analytes included serum concentrations of WBC (white blood cell, Â10 9 /L), neutrophils (N), neutrophils percentage (NP), RBC (red
and BUN/CR (blood urea nitrogen to creatinine ratio), serum activities (U/L) of ALT (alanine aminotransferase), AST (aspartate aminotransferase), LDH (lactate dehydrogenase), GGT (gamma glutamyltransferase), and ALP (alkaline phosphatase).
Data analyses
Concentrations of VPA and 4-ene VPA were presented as mg/ml. 
Method validation
For VPA and 4-ene VPA, the calibration curve was linear over the range of 5-200 mg/ml and 0.5-20 mg/ml, respectively. The LOQ for both components was 5 and 0.5 mg/ml, respectively; and the intraand inter-day precision were lower than 12.4%, the intra-and inter-day accuracy were within the range of À3.0% to 7.5% (Table  1) . No significant degradation of VPA and 4-ene VPA in plasma was observed under various storage conditions, including at room temperature for 4 h, frozen-thawed three times, and frozen at À20 8C for 1 month ( Table 2 ). All these parameters meet FDA requirements for biosample analyses.
Plasma concentrations of VPA and 4-ene VPA in patients with epilepsy
Plasma concentrations of VPA and 4-ene VPA in 64 Chinese patients with epilepsy treated with divalproex sodium twice daily for one month are shown in Table 3 . The concentrations of VPA and 4-ene VPA ranged from 8.05 to 139 mg/ml and from 1.02 to 12.2 mg/ ml, respectively, with 32.8% samples (21 out of 64) falling out of the recommended therapeutic monitoring range (50-100 mg/ml). The total average concentrations of both components in the 64 subjects are 74.4 AE 28.3 mg/ml and 4.06 AE 2.31 mg/ml, respectively. In the children group (<16 years old), the concentrations of VPA and 4-ene VPA are 4.24 AE 1.95 mg/ml/kg/day and 0.19 AE 0.11 mg/ml/kg/day, respectively. In the adults group (!16 years old), the corresponding respectively. The statistically significant difference in the concentrations of VPA and 4-ene VPA is very evident between these two groups (p < 0.05). In the gender groups, there is no significant difference in the plasma concentrations of VPA and 4-ene VPA.
Biochemical analysis
We tested the levels of WBC, N, NP, RBC, PLT, Hb, BUN, CR, BUN/CR, ALT, AST, LDH, GGT, and ALP in the blood in order to evaluate the toxic effects of VPA and 4-eve VPA. The average value for each measure see Table 3 , there were 9.37%, 9.37%, 31.3%, 10.9%, 7.81%, 10.9%, 3.85%, 23.1%, 21.9%, 7.81%, 6.25%, 7.81%, 6.25% and 48.9% samples beyond the normal values of WBC, N, NP, RBC, PLT, Hb, BUN, CR, BUN/CR, ALT, AST, LDH, GGT, and ALP, respectively.
Correlations of plasma concentrations of VPA and 4-ene VPA with biochemical measures
The bivariate correlations of the VPA doses, concentrations of VPA, 4-ene VPA with blood biochemical indicators in Chinese patients with epilepsy are shown in Table 4 . The concentrations of VPA and 4-ene VPA had no significant correlations with the VPA dosage. The plasma concentrations of 4-ene VPA were positively correlated with VPA concentrations (with correlation coefficient (r) of 0.473, p < 0.01). There was significant negative correlation of PLT (r = À0.352) and BUN/CR (r = À0.484) with VPA dosage, and D VPA = VPA dose; C VPA = concentrations of VPA; C VPAdw = C VPA /dose/body weight; C eVPA = concentrations of 4-ene VPA; C eVPAdw = concentrations of 4-ene VPA/dose/body weight. Bold means statistically significant correlation. * Correlation is significant at p < 0.05 level (2-tailed). ** Correlation is significant at p < 0.01 level (2-tailed).
significant negative correlation of PLT (r = À0.381) and CR (r = À0.392) with VPA plasma concentrations (p < 0.05). Furthermore, significant positive correlations of the AST (r = 0.359) and ALT (r = 0.282) with plasma concentrations of 4-ene VPA were observed in the Chinese patients with epilepsy (p < 0.05).
Discussion
4.1. Correlations of concentrations of VPA and 4-ene VPA with adverse effects of VPA
The anticonvulsant properties of VPA were first described in 1967. It has proven to be a broad-spectrum antiepileptic drug indicated in various forms of epilepsy of adults and the children. The foremost and most severe concern for anyone taking VPA is its potential for sudden and severe, possibly fatal, fulminating impairments in liver and hematopoietic function, especially in those just starting the medication. In addition, cases in which individuals taking long-term VPA suffered from renal impairment have been reported. In this study, we explored the correlation of the concentrations of VPA and 4-ene VPA with hematopoietic, renal and hepatic function, which were represented by the levels of WBC/RBC/PLT, BUN/CR, and ALT/AST/ALP/LDH.
In our study, we found the VPA dosage and/or VPA concentrations was significantly negatively correlated with the level of PLT, which can be interpreted as an indicator of hematopoietic functions, suggesting that VPA can damage the platelet membrane by decreasing the production of platelet malonyldialdehyde. 20 The result was consistent with the results of previous studies that lower platelet levels were noted in patients with higher VPA concentrations. 21, 22 The values of BUN/CR, a biochemical marker of renal dysfunction, were below the normal value in 23.1% patients. Furthermore, its values significantly (p < 0.05) correlated with the plasma concentrations of VPA. The results suggested that the clinical monitoring of VPA concentrations may help to minimise its renal and hematopoietic adverse effects. The serum levels of AST, ALT, LDH, GGT, and ALP were chosen as markers of hepatocellular injury. 23, 24 The results revealed that these biochemical indicators exceeded normal values in many patients. To date, several preclinical study have indicated that 4-ene VPA is the most hepatotoxic metabolite of VPA, but there was very limited published data about the association between plasma levels of 4-ene VPA and hepatotoxicity, 25 except a study conducted in rats. 26 In the present study, significant positive correlations of the AST and ALT with plasma concentrations of 4-ene VPA were observed in the Chinese patients with epilepsy (p < 0.05). Since AST and ALT have been most extensively used as routine enzymatic markers of hepatocellular injury in clinical practice, 27 the results indicated that blood 4-ene VPA concentrations may predict the hepatotoxicity of VPA. Further research is ongoing to explore the relationship between the plasma VPA and 4-ene VPA concentrations, genotypes of the enzymes and transporters involved in the metabolism and elimination, efficacy and the adverse reactions of VPA in epileptic patients treated with divalproex sodium.
Factors influencing the concentrations of VPA and 4-ene VPA
VPA exhibits a complex pharmacokinetic profile. Many investigations have demonstrated that age, dosage and comedications are the most important factors that lead to significant intra-and inter-individual pharmacokinetic profiles. In our study, the statistically significant difference in the steady state trough concentrations of VPA and 4-ene VPA was observed between adults and children groups (p < 0.05). Meanwhile, the study showed a poor dose-concentration relationship, partially due to the variability of dosage. This result is consistent with other reports. 28 Some studies have shown that co-medications will increase the concentration of VPA and aggravate liver damage, especially the combination of VPA with phenobarbital and carbamazepine. Now we know that these agents are inducers of CYP2C9, which will accelerate VPA conversion to 4-ene VPA. Most importantly, our research found that the concentrations of VPA and 4-ene VPA vary greatly in different ethnic groups. The average VPA plasma concentration in Chinese (74.4 AE 28.3 mg/ml) was comparable to those in the United States (80 mg/ml), 18 but less than those in Iran (294 AE 82.7 mg/ml). 29 However, the concentration of 4-ene VPA (4.06 AE 2.31 mg/ml) in Chinese patients with epilepsy was much higher than those in the residents in the United States (a steady state at 250 ng/ml) 18 and Iran (129 AE 52.4 ng/ml), 29 although it was comparable with that in a recent study performed in Shanghai, China (about 4000 ng/ml). 19 Previous studies revealed that 4-ene VPA is predominantly produced by human CYP2C9 with several allelic variants, [30] [31] [32] whose inter-population variation in CYP2C9 expression is significant. 32 For example, Caucasians appear to carry the CYP2C9*2 (8-20%) and CYP2C9*3 (6-10%) variants more frequently than Asians (0% and 2-5%, respectively). 33 Therefore, Asians may have the higher CYP2C9 activity and higher production of 4-ene VPA compared with white people.
Applicability of the present HPLC-UV method in Chinese patients with epilepsy
In the present study, a simple and efficient HPLC-UV method for in vivo quantification of VPA and its toxic metabolite 4-ene VPA was developed and validated. As shown in Scheme 1, the derivatization regent (2, 4 0 -dibromoacetophenone) provided a good chromophore with VPA, 4-ene VPA and IS according to a previous study. 34, 35 The chromatograph was equipped with a UV detector tuned to 254 nm. For VPA and 4-ene VPA, the linearity range was 5-200 mg/ml and 0.5-20 mg/ml, respectively. The LLOQ for the two compounds is 5 mg/ml and 0.5 mg/ml, respectively. This means that the method is sensitive enough for the concentration determination of VPA and 4-ene VPA in Chinese patients with epilepsy in whom the concentrations of VPA and 4-ene VPA approximately ranged between 8.05-139 mg/ ml and 1.02-12.2 mg/ml, respectively. Although some of the reported HPLC-MS/MS methods are more sensitive than our HPLC-UV method in determination of the plasma concentrations of VPA and 4-ene VPA, not all the hospitals in China can afford this kind of instrument since it is too expensive with the price of RMB 500,000 (about USD 78,000 or EURO 59,000) or more. In fact, few hospitals in Guangzhou own HPLC-MS/MS instrument. In contrast, HPLC-UV is very popular in Chinese hospitals because the set up costs are much lower at RMB 30,000 (about USD 4700 or EURO 3500). The present determination method makes it possible for most hospitals in developing countries like China to perform TDM of VPA and to conduct multicenter clinical trials to obtain more information about the concentration-effect relationship to guide the clinical use of VPA and guarantee its safety and efficacy.
Conclusion
Our study first reports a significant relationship between AST/ ALT levels and 4-ene VPA plasma concentration. It suggests that there are ethnic differences in the plasma concentration of 4-ene VPA, which mean that monitoring of 4-ene VPA is particularly important in Chinese populations. The simple, sensitive and costeffective HPLC-UV method we have developed here will make multicenter clinical trials of VPA in China possible, which will demonstrate whether prospective monitoring of VPA and 4-ene VPA levels can reduce clinically significant hepatotoxicity.
